Nothing Special   »   [go: up one dir, main page]

SG11201609497TA - Compounds for treating spinal muscular atrophy - Google Patents

Compounds for treating spinal muscular atrophy

Info

Publication number
SG11201609497TA
SG11201609497TA SG11201609497TA SG11201609497TA SG11201609497TA SG 11201609497T A SG11201609497T A SG 11201609497TA SG 11201609497T A SG11201609497T A SG 11201609497TA SG 11201609497T A SG11201609497T A SG 11201609497TA SG 11201609497T A SG11201609497T A SG 11201609497TA
Authority
SG
Singapore
Prior art keywords
compounds
muscular atrophy
spinal muscular
treating spinal
treating
Prior art date
Application number
SG11201609497TA
Other languages
English (en)
Inventor
Hasane Ratni
Luke Green
Nikolai A Naryshkin
Marla L Weetall
Original Assignee
Hoffmann La Roche
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53175048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201609497T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Ptc Therapeutics Inc filed Critical Hoffmann La Roche
Publication of SG11201609497TA publication Critical patent/SG11201609497TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201609497TA 2014-05-15 2015-05-11 Compounds for treating spinal muscular atrophy SG11201609497TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461993839P 2014-05-15 2014-05-15
PCT/EP2015/060343 WO2015173181A1 (en) 2014-05-15 2015-05-11 Compounds for treating spinal muscular atrophy

Publications (1)

Publication Number Publication Date
SG11201609497TA true SG11201609497TA (en) 2016-12-29

Family

ID=53175048

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201609497TA SG11201609497TA (en) 2014-05-15 2015-05-11 Compounds for treating spinal muscular atrophy

Country Status (36)

Country Link
US (1) US9969754B2 (ru)
EP (3) EP3663296B1 (ru)
JP (1) JP6236173B2 (ru)
KR (2) KR102213740B1 (ru)
CN (1) CN106459092B (ru)
AR (1) AR100442A1 (ru)
AU (1) AU2015261046C1 (ru)
BR (1) BR112016026205B1 (ru)
CA (1) CA2948561C (ru)
CL (1) CL2016002836A1 (ru)
CR (1) CR20160518A (ru)
DK (1) DK3143025T3 (ru)
EA (2) EA035068B1 (ru)
ES (2) ES2761423T3 (ru)
FR (1) FR21C1039I2 (ru)
HR (2) HRP20230637T1 (ru)
HU (2) HUE046491T2 (ru)
IL (2) IL248653B (ru)
LT (1) LTPA2021010I1 (ru)
MA (2) MA51988A (ru)
MX (1) MX371050B (ru)
MY (1) MY174284A (ru)
NL (1) NL301128I2 (ru)
NO (1) NO2021035I1 (ru)
NZ (1) NZ725008A (ru)
PE (1) PE20170128A1 (ru)
PH (1) PH12016502081A1 (ru)
PL (2) PL3663296T3 (ru)
PT (1) PT3143025T (ru)
RS (1) RS59718B1 (ru)
SG (1) SG11201609497TA (ru)
SI (2) SI3143025T1 (ru)
TW (1) TWI667239B (ru)
UA (1) UA119670C2 (ru)
WO (1) WO2015173181A1 (ru)
ZA (1) ZA201607026B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116981C2 (uk) 2012-02-10 2018-06-11 ПіТіСі ТЕРАП'ЮТІКС, ІНК. Сполуки для лікування спінальної м'язової атрофії
WO2015024876A2 (en) 2013-08-19 2015-02-26 F. Hoffmann-La Roche Ag Screening method
US10882868B2 (en) * 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
EP3298017B1 (en) 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Compounds for treating spinal muscular atrophy
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
JP6659841B2 (ja) * 2015-11-12 2020-03-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脊髄性筋萎縮症を処置するための組成物
AU2016351919B2 (en) * 2015-11-12 2020-11-12 F. Hoffmann-La Roche Ag Compounds for treating amyotrophic lateral sclerosis
CN108137579B (zh) 2015-12-10 2022-01-07 豪夫迈·罗氏有限公司 桥连哌啶衍生物
MX2021001091A (es) 2015-12-10 2022-04-26 Ptc Therapeutics Inc Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington.
US11702646B2 (en) 2016-11-28 2023-07-18 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
MX2019014514A (es) 2017-06-05 2020-07-20 Ptc Therapeutics Inc Compuestos para tratar la enfermedad de huntington.
EP3638318A4 (en) 2017-06-14 2021-03-17 PTC Therapeutics, Inc. METHOD OF MODULATION OF RNA SPLICING
EP3644996B1 (en) 2017-06-28 2023-07-26 PTC Therapeutics, Inc. Methods for treating huntington's disease
CA3067592A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
CA3075968C (en) 2017-09-22 2023-04-04 F. Hoffmann-La Roche Ag Process for the preparation of 7-(4,7-diazaspiro[2,5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives
JP7423515B2 (ja) * 2017-10-03 2024-01-29 エフ． ホフマン－ラ ロシュ アーゲー Ｓｍａの新たな処置
AU2019243048A1 (en) 2018-03-27 2020-10-15 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
BR112020026637A2 (pt) 2018-06-27 2021-03-30 Reborna Biosciences, Inc. Agente profilático ou terapêutico para atrofia muscular espinhal
EP4434990A1 (en) 2018-06-27 2024-09-25 PTC Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
JP2022505098A (ja) 2018-10-19 2022-01-14 エフ．ホフマン－ラ ロシュ アーゲー ピリド［１，２－ａ］ピリミジン－４－オン誘導体の新規な形態、その製剤およびその製造プロセス
CN113966219A (zh) 2019-06-12 2022-01-21 豪夫迈·罗氏有限公司 Sma的新治疗方法
EP4004003A1 (en) 2019-07-31 2022-06-01 Teva Pharmaceuticals International GmbH Solid state forms of risdiplam and process for preparation thereof
WO2022048675A1 (zh) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Risdiplam晶型及其制备方法和用途
WO2022162107A1 (en) 2021-02-01 2022-08-04 Sandoz Ag Crystalline form of risdiplam
EP4308577A1 (en) * 2021-03-17 2024-01-24 F. Hoffmann-La Roche AG New thiadiazolopyrimidone derivatives
CR20230437A (es) 2021-03-17 2023-10-16 Hoffmann La Roche Nuevos derivados de tiazolopirimidinona
AU2022237836B2 (en) 2021-03-18 2024-07-04 F. Hoffmann-La Roche Ag Process for preparing risdiplam
CN118055767A (zh) 2021-10-06 2024-05-17 豪夫迈·罗氏有限公司 新颖的组合施用
WO2023202501A1 (zh) * 2022-04-18 2023-10-26 深圳市塔吉瑞生物医药有限公司 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
WO2024069646A1 (en) * 2022-09-26 2024-04-04 Natco Pharma Limited Improved process for the preparation of risdiplam and its intermediates
US20240173325A1 (en) 2022-10-14 2024-05-30 Genentech, Inc. Methods for treating spinal muscular atrophy
WO2024154148A1 (en) * 2023-01-21 2024-07-25 Harman Finochem Limited Process for preparation of risdiplam, novel intermediates, and process for preparation thereof
WO2024218207A1 (en) 2023-04-20 2024-10-24 F. Hoffmann-La Roche Ag Thieno[3,2-b]pyridine derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1093130C (zh) * 1996-08-06 2002-10-23 辉瑞大药厂 被取代的吡啶并6,6－二环衍生物
EP2215074B1 (en) 2007-09-27 2014-02-19 The United States of America, as Represented by the Secretary, Department of Health and Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US8633019B2 (en) * 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
KR20100012134A (ko) * 2008-07-28 2010-02-08 신호열 마우스
US8932818B2 (en) 2008-08-13 2015-01-13 Ptc Therapeutics, Inc. Screening assays for compounds that modulate programmed ribosomal frameshifting
JP2011529722A (ja) * 2008-08-14 2011-12-15 カーディアック ペースメイカーズ， インコーポレイテッド 音響通信リンクの性能評価および適合
CN104244944B (zh) * 2011-12-30 2018-06-08 Ptc医疗公司 用于治疗脊髓性肌萎缩症的化合物
UA116981C2 (uk) * 2012-02-10 2018-06-11 ПіТіСі ТЕРАП'ЮТІКС, ІНК. Сполуки для лікування спінальної м'язової атрофії
WO2014012050A2 (en) 2012-07-13 2014-01-16 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
JP6659841B2 (ja) 2015-11-12 2020-03-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脊髄性筋萎縮症を処置するための組成物

Also Published As

Publication number Publication date
EP3143025A1 (en) 2017-03-22
MX2016014547A (es) 2017-02-23
AU2015261046A1 (en) 2016-10-27
IL248653A0 (en) 2017-01-31
CA2948561C (en) 2019-10-22
HUS2100037I1 (hu) 2021-10-28
CR20160518A (es) 2017-02-21
US20170197990A1 (en) 2017-07-13
NO2021035I1 (no) 2021-09-10
HRP20230637T1 (hr) 2023-09-29
BR112016026205A8 (pt) 2021-07-20
CA2948561A1 (en) 2015-11-19
CN106459092A (zh) 2017-02-22
CL2016002836A1 (es) 2017-04-21
BR112016026205B1 (pt) 2021-12-07
RS59718B1 (sr) 2020-01-31
KR20170003687A (ko) 2017-01-09
EA201692280A1 (ru) 2018-07-31
TWI667239B (zh) 2019-08-01
EA202090486A2 (ru) 2020-06-30
HRP20192159T1 (hr) 2020-02-21
NL301128I2 (nl) 2021-10-25
EP4241772A3 (en) 2023-11-15
EP3663296A1 (en) 2020-06-10
NZ725008A (en) 2019-11-29
PE20170128A1 (es) 2017-03-16
ES2761423T3 (es) 2020-05-19
CN106459092B (zh) 2019-10-15
IL270027B (en) 2020-08-31
US9969754B2 (en) 2018-05-15
PT3143025T (pt) 2019-12-03
KR102256013B1 (ko) 2021-05-26
EA035068B1 (ru) 2020-04-23
MA51988A (fr) 2021-01-20
PL3143025T3 (pl) 2020-03-31
MY174284A (en) 2020-04-01
EP4241772A2 (en) 2023-09-13
MX371050B (es) 2020-01-14
UA119670C2 (uk) 2019-07-25
SI3663296T1 (sl) 2023-08-31
PH12016502081A1 (en) 2017-01-09
TW201609738A (zh) 2016-03-16
NL301128I1 (ru) 2021-09-22
AR100442A1 (es) 2016-10-05
ES2949660T3 (es) 2023-10-02
KR20210014219A (ko) 2021-02-08
EP3663296B1 (en) 2023-05-17
IL248653B (en) 2019-11-28
EP3143025B1 (en) 2019-10-09
AU2015261046C1 (en) 2019-07-25
WO2015173181A1 (en) 2015-11-19
BR112016026205A2 (pt) 2017-08-15
AU2015261046B2 (en) 2019-04-18
PL3663296T3 (pl) 2023-08-07
JP2017515863A (ja) 2017-06-15
JP6236173B2 (ja) 2017-11-22
KR102213740B1 (ko) 2021-02-09
ZA201607026B (en) 2022-05-25
LTPA2021010I1 (ru) 2021-10-11
HUE046491T2 (hu) 2020-03-30
FR21C1039I1 (ru) 2021-10-15
FR21C1039I2 (fr) 2022-09-02
SI3143025T1 (sl) 2020-01-31
EA202090486A3 (ru) 2020-08-31
MA39995B1 (fr) 2019-11-29
DK3143025T3 (da) 2019-12-09

Similar Documents

Publication Publication Date Title
HUS2100037I1 (hu) Vegyületek gerinc eredetû izomsorvadás kezelésére
HK1256089A1 (zh) 用於治療脊髓性肌萎縮的組合物
HK1215399A1 (zh) 用於治療脊髓性肌萎縮的化合物
HK1246784A1 (zh) 用於治療脊髓性肌萎縮的化合物
HK1258823A1 (zh) 用於治療肌營養不良的方法
HK1244217A1 (zh) 用於治療蛋白質病的方法
EP3354288C0 (en) STERILIZATION DEVICE
PL3160913T3 (pl) Sposób oczyszczania osadu biologicznego
EP3302695B8 (en) Devices for treating muscles
GB201405132D0 (en) Fixation apparatus
GB201715519D0 (en) Hand treatment apparatus
HK1248130A1 (zh) 用於治療疼痛的組合物
IL231816A0 (en) Devices for the treatment of bone fractures
GB2534681B (en) Treatment apparatus
GB201604658D0 (en) Treatment for pain
PT3250218T (pt) Péptido natkide para o tratamento da obesidade
ZA201800752B (en) Improved prosthesis for osteosynthesis
PL3129031T3 (pl) Kompozycja do terapii zaburzeń żołądkowych
PL3194551T3 (pl) Stała kompozycja do traktowania tekstyliów
GB201507044D0 (en) Waste treatment
GB201505205D0 (en) Treatment for pain
GB201504688D0 (en) Treatment for pain